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Abstract
Background: The aim of the study was to demonstrate the immunohistochemical expression of proteins that affect
the metastatic potential of a tumour, including matrix metalloproteinase 2 (MMP-2) and E-cadherin. Another objective
was to determine their correlation with the expression of the Ki-67 antigen in metastasizing and non-metastasizing
mammary carcinomas in female dogs. The study was conducted on 32 canine mammary carcinomas (12 metastatic
and 20 non-metastatic), classified as simple tubular and tubulopapillary carcinomas. Immunohistochemistry was
performed to evaluate the expression of MMP-2, E-cadherin and Ki-67 antigen.
Results: MMP-2 was expressed in 85 % of the non-metastatic tumours and in all the metastatic tumours, while
E-cadherin was expressed in 85 % of the non-metastatic tumours and in 66 % of the metastatic tumours. The
Ki-67 antigen was expressed in 65 % of the non-metastatic tumours and in 91 % of the metastatic tumours. The mean
Ki-67 expression was slightly higher in tumours that had metastasized (1.5 ± 0.90 vs 1.1 ± 0.94; p = 0.22). A similar
relationship was found in terms of the intensity of the MMP-2 expression (2.9 ± 1.9 vs 2.7 ± 2.4; p = 0.50). A decrease in
the expression of E-cadherin (2.8 ± 2.5) was found in metastatic tumours compared to the expression in non-metastatic
tumours (3.2 ± 2.3). However, these differences were not statistically significant (p = 0.63).
Conclusion: We did not show significant differences in MMP-2, E-cadherin and Ki-67 expression between metastatic
and non-metastatic tumours due to low number of cases studied, however further experiments are necessary to assess
the role of these antigens in the process of canine mammary tumours metastasis.
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Background
In order to invade, the neoplastic cell released from a
primary tumour has to overcome a dense extracellular
matrix (ECM) of proteins comprised of collagen, laminin,
fibronectin, vitronectin and many other particles, which
together form the basement membrane (BM). This mem-
brane forms a mechanical barrier between the epithelium
or endothelium and the surrounding tissue [1]. The ability
of tumour cells to degrade components of the ECM is
directly associated with their metastatic potential [2].
Matrix metalloproteinases (MMPs) are enzymes that play
an important role in the destruction of the ECM.
Metalloproteinases are Zn2+ dependent proteases [3],
which are mainly produced in fibroblasts, monocytes,
leukocytes, macrophages, neutrophils, endothelial cells
and are secreted by tumour cells [4, 5]. The vascular
endothelial growth factor (VEGF), tumour necrosis
factor alpha (TNF-α), interleukin-1 (IL-1) and prosta-
glandin (PG) were shown to stimulate the synthesis of
MMPs [5]. The gelatinases, particularly MMP-2 and
MMP-9, are thought to play an important role in
carcinogenesis. Their increased expression and correlation
with unfavourable prognostic factors have been found in
human and canine breast cancer [6–12]. Those proteinases
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lead to a breakdown of type IV collagen, which constitutes
the basement membrane scaffolding, including that of the
vascular endothelium. This facilitates the intravasation of
tumour cells, which is an important stage of metastasis.
The mechanism through which a cell metastasizes and
adheres to the target site is not fully understood. However,
this process always involves the release of a tumour cell
from the primary malignancy. Cells require various chem-
ical signals (cytokines, chemokines, hormones, neurotrans-
mitters) to begin migration. Cellular adhesion molecules
(CAM), located in cell membranes, play an important role
at this stage of the metastatic cascade. The level of their ex-
pression influences the strength of connections between
the neighbouring cells [13, 14]. There are four main classes
of adhesion molecules: cadherins, integrins, selectins and
immunoglobulin-like particles. Cadherin plays an important
role in the invasion and metastasis of the tumour [15]. It is
a calcium-dependent transmembrane protein [8]. Three
major molecules are included in this group: E-cadherin
(Epithelial-cadherin), N-cadherin (Neuronal cadherin)
and P-cadherin (Placental cadherin). Cadherins connect to
neighbouring cells by binding to other cadherins through
an extracellular N-terminal amino acid sequence of His-
Ala-Val. The cytoplasmic domain of E-cadherin binds to a
group of interconnected proteins, called catenins (α, β and
γ). β and γ-catenins compete with one another and directly
bind to E-cadherin. α-catenin, on the other hand, connects
E-cadherin to actin F and α-actinin, which constitute the
cell cytoskeleton [14]. Any functional disturbances in the
cadherin-catenin complex (dysfunction and/or a lack of
cadherin or catenin) reduce cell adhesion and disturb cel-
lular differentiation. This leads to an increase in the inva-
sive potential of the tumour and may support metastasis
[16]. It has been shown that transfection of a murine
mammary tumour cell line with E-cadherin cDNA de-
creases its invasiveness [17]. This underlines the im-
portance of E-cadherin in the acquisition of a
malignant phenotype of tumour cells.
The aim of this study was to demonstrate the ex-
pression (tumour cell positivity as well as expression
intensity) of proteins associated with the metastatic
potential of mammary gland carcinomas, i.e., MMP-2
and E-cadherin. We also aimed to determine the en-
hancement of their expression when correlated with
the expression of the Ki-67 antigen in canine mam-
mary carcinomas. The expression of Ki-67 can be ob-
served already during G1 phase of the cell cycle; it
increases markedly during S and G2 phases, reaches
its peak level during M phase, and is absent in G0
cells. Consequently, Ki-67 is detected mostly in prolif-
erating cells [18, 19]. Furthermore, the expression of
the studied markers in metastatic tumours was com-
pared to the results obtained from the tumours that
had not metastasized.
Methods
The material for the study was sampled during surgery
from 32 female dogs of various breeds, 8 to 14 years old.
The tumours were verified as carcinomas based on a
histopathological examination according to the classi-
fication by Goldschmidt et al. [20] as simple tubular
(n = 17) and simple tubulopapillary carcinomas (n = 15) (12
cases with lymph node metastasis – diagnosed based on a
fine needle biopsy, and 20 cases without metastasis follow-
ing a 2 year observation). In order to confirm or rule out
metastasis, the female dogs were examined 2 months after
the surgical tumour removal. Thoracic radiography and
abdominal ultrasonography were carried out in each dog.
In every case, samples from the superficial inguinal or/and
axillary lymph nodes (which have not been removed during
mastectomy) were obtained by using a fine needle biopsy.
Those examinations were repeated every 6 months.
Formalin-fixed, paraffin-embedded tissues were freshly
cut into 4-μm- thick sections and mounted on Superfrost
Plus slides (Menzel Gläser, Braunschweig, Germany). The
sections were then dewaxed with xylene and gradually
hydrated in alcohol. The activity of the endogenous perox-
idase was blocked by a 5 min exposure to 3 % H2O2. The
sections were then boiled in a microwave oven for 15 min
in an Antigen Retrieval Solution [21, 22] (DakoCytomation,
Glostrup, Denmark). In order to measure the levels of the
studied antigens, the following antibodies were applied for
1 hour at room temperature (RT) in the following concen-
trations: polyclonal rabbit anti-MMP-2 (1:100; Chemicon
Millipore, Billerica, MA, USA), monoclonal mouse anti-E-
cadherin antibody (clone NCH-38, 1:150; DakoCytomation),
monoclonal mouse anti-Ki-67 (clone MIB-1, 1:100;
DakoCytomation). All the utilized antibodies were di-
luted in the Background Reducing Antibody Diluent
(DakoCytomation). Next, the samples were incubated
(15 min, RT) with secondary biotinylated antibodies
and a streptavidin-horseradish peroxidase complex (LSAB2,
HRP, DakoCytomation). The 3,3'-diaminobenzidine (7 min,
room temperature, DakoCytomation) served as a substrate
for the reaction. All the sections were counterstained with
Meyer’s haematoxylin. In all the cases, controls were
assessed and the specific antibody was substituted with
the Primary Negative Control (DakoCytomation). Micro-
photographs of all the studied tumours were subjected to
a computer-aided image analysis via a computer coupled
to a BX53 optical microscope (Olympus, Tokyo, Japan).
The set was able to record images and to analyse them
digitally. The measurements were carried out using the
CellA software (Olympus Soft Imaging Solution GmbH,
Germany).
The expression of MMP-2 and E-cadherin was ap-
praised using the modified semiquantitative IRS scale
according to Remmele and Stegner [12, 23]. The method
takes into account both the proportion of positively
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stained tumour cells and the intensity of the reaction
colour, while its final result represents the product of
both parameters, with values ranging from 0 to 12 points
(no reaction = 0 points (−); weak reaction = 1–2 points (+),
moderate reaction = 3–4 points (++), intense reaction =
6–12 points (+++)). The expression of the Ki-67 antigen
was evaluated quantitatively by estimating the percentage
of positive tumour cells (0–5 % = no reaction (0 points),
6–25 % =weak reaction (1 point), 26–50 % =moderate re-
action (2 points), above 50 % = intense reaction (3 points)).
For purpose of the statistical analysis the final IRS scores
of MMP-2 and E-cadherin, as well as Ki-67 score for par-
ticular cases were used for deriving the mean values. All
the analyses were performed by two independent patholo-
gists, and in case of discrepant results, the sections were
re-evaluated until a consensus was achieved.
The results were subjected to a statistical analysis using
Prism 5.0 (GraphPad, La Jolla, CA, USA). The differences
between the two groups were compared using the non-
parametric test of Mann-Whitney, whereas associations
between the expression of the analysed markers were
assessed using the Spearman correlation and Fisher exact
test. The results were considered significant at p < 0.05 in
all the analyses. For purpose of statistical analysis the ex-
pression of studied antigens was dichotomized into low
(none, low and moderate expression of studied markers)
and high (intense expression) expressing tumours.
Results and discussion
MMP-2 was expressed in tumour cells in 17 out of 20
(85 %) of the non-metastatic tumours and in all the
metastatic tumours, while E-cadherin was expressed in
17 out of 20 (85 %) of the non-metastatic tumours and in 8
out of 12 (66 %) of the metastatic tumours (Fig. 1a and b).
The Ki-67 antigen was found to be expressed in tumour
cell nuclei of 13 out of 20 (65 %) non-metastatic carcin-
omas. In case of metastatic tumours 11 out of 12 (91 %)
cases were positive (Fig. 1c). The results of encoded ex-
pression of the analysed markers is presented in Table 1.
Statistical analysis revealed that intense Ki-67 antigen ex-
pression was associated with intense MMP-2 expression in
the non-metastatic tumors (p = 0.03) (Table 2).
Higher expression of MMP-2 (2.9 ± 1.9 vs 2.7 ± 2 .4;
p = 0.50; Fig. 2a) could be noted in the tumours that
metastasized in comparison to that noted in the non-
metastatic tumours. On the contrary, the expression of
E-cadherin was lower in the tumours that metastasized
(2.8 ± 2.5) compared to those that did not (3.2 ± 2.3).
However, those differences were not statistically signifi-
cant (p = 0.63; Fig. 2b). In accordance to the observed
increase of Ki-67 antigen expression positivity with
metastatic potential in the analysed tumours, its average
expression was slightly higher in tumours that metasta-
sized (1.5 ± 0.90 vs 1.1 ± 0.94; p = 0.22; Fig. 2c) than in
those that did not. The Spearman’s correlations test did
not show any statistically significant correlations between
the expression intensities of the studied markers in the
two groups of carcinomas.
Comparing metastatic and non-metastatic carcinomas,
metastatic carcinomas showed lower E-cadherin expression
Fig. 1 Immunoexpression of studied cell markers in canine mammary
gland carcinoma. a High cytoplasmic expression of MMP-2 in carcinoma
cells (simple tubular carcinoma, non-metastatic). b E-cadherin expression
was predominantly found in the membrane of neoplastic cells (simple
tubulopapillary carcinoma, non-metastatic). c Expression of Ki-67 localized
in tumour cell nuclei (simple tubular carcinoma, metastatic)
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and a high Ki-67 expression. This may indicate that the
greater the number of mitotic neoplastic cells in the
tumour, the weaker the intercellular connections (fewer E-
cadherin adhesion molecules on their surface), and the
easier it is for the cells to be released from the tumour.
However, in our study, the observed trend did not reach
statistical significance. Nevertheless, similar findings were
demonstrated in a study of more than 100 women with
breast cancer [14]. In that study, there was a complete loss
of expression of E-cadherin in 64 % of lobular carcinomas
and 19 % of ductal carcinomas. In our study, E-cadherin
was not expressed in 34 % of metastasized and in 15 % of
non-metastasized tumours. Interestingly we found that
intense expression of MMP-2 was associated with intense
Ki-67 antigen expression in the non-metastasizing tumours.
Two explanations of this phenomenon are possible. First,
these tumours may be regarded as being resected in direct
preinvaseve state in which case the loss of E-cadherin
expression could be the next step in acquirement of
invasive properties. Secondly, this may be a random
non-significant finding due to small sample size. Never-
theless, further analyses on larger cohorts are necessary
to fully address this issue.
The expression of E-cadherin was found to be de-
creased in breast cancer and a positive correlation was
found between its expression and the frequency of
metastasis by Acs et al. and Bankfalvi et al. [24, 25].
Few studies were carried out on malignant breast tumours
in dogs. They revealed that tumours with a decreased ex-
pression of E-cadherin grew more aggressively and metas-
tasized more often [26, 27].
Our current findings indicate that the increase in the
metastatic potential of tumour cells is associated with an
increased expression of MMP-2 and a decreased expres-
sion of E-cadherin. These results are similar to our previ-
ous findings concerning the expression of MMP-9 [12].
However, the intensity of expression of those markers did
not correlate. Nevertheless, our observations support the
suggested biological role of these proteins in the metastatic
process. The decrease in the expression of E-cadherin and
increase in the expression of MMP-2 leads to a loss of cell
cohesion and potentiates the degradation of the extracellu-
lar matrix. The lack of correlation between the expressions
of the three proteins in our study was most likely due to
the high biodiversity of canine mammary tumors. However,
the role of E-cadherin, MMP-2 and Ki-67 in the metastatic
process seems crucial.
The comparable expression of Ki-67 and MMP-2 that
was obtained in our study in both metastasizing and
non-metastasizing carcinomas may suggest an increased
Table 1 Expression intensities of studied markers grouped and encoded according to established assessment scales
Number of cases (% of cases)
Expression intensity Non-metastatic MMP-2 Metastatic MMP-2 Non-metastatic E-cad Metastatic E-cad Non-metastatic Ki-67 Metastatic Ki-67
None 3 (15.0) 0 (0.0) 3 (15.0) 4 (33.3) 7 (35.0) 1 (8.4)
Weak 9 (45.0) 6 (50.0) 8 (40.0) 2 (16.7) 6 (30.0) 6 (50.0)
Moderate 5 (25.0) 5 (41.6) 2 (10.0) 3 (25.0) 6 (30.0) 3 (25.0)
Intense 3 (15.0) 1 (8.4) 7 (35.0) 3 (25.0) 1 (5.0) 2 (16.4)
Table 2 Distribution of studied antigens in relation to their intensity in metastatic and non-metastatic tumours (low = none +
weak + moderate; high = intense)
Lesion and marker type No. Non-metastatic Ki-67 p-value No. Metastatic Ki-67 p-value
High Low High Low
Non-metastatic MMP-2 20 No. (%) No. (%) No. (%) No. (%)
High 3 3 (100) 0 (0.0) 0.03
Low 17 4 (23.5) 13 (76.5)
Metastatic MMP-2 12 12
High 1 1 (100) 0 (0.0) 0.41
Low 11 4 (36.4) 7 (73.6)
Non-metastatic E-cadherin 20
High 7 2 (28.5) 5 (71.5) 1.00
Low 13 5 (38.4) 8 (61.6)
Metastatic E-cadherin 12
High 3 1 (33.3) 2 (66.7) 1.00
Low 9 4 (44.4) 5 (55.6)
Nowak et al. Irish Veterinary Journal  (2016) 69:9 Page 4 of 6
expression of MMP-2 in cells undergoing rapid division.
Such co-expression may facilitate the disintegration of
the stroma and the spread of rapidly dividing tumour
cells. However, more detailed studies using an in vitro
approach are warranted to elucidate this matter in canine
mammary cancers.
That point of research was mostly addressed in human
breast cancer, where the prognostic role of MMPs was
intensively studied. Lu et al. [28] analysed 21 cases of
mammary carcinomas in women and found that MMP-2
plays an important part in the metastasis of those tumours
to regional lymph nodes. In addition, the authors found a
significantly higher MMP-2 expression in the metastasis
(lymph node) than in the primary tumour. An increased
MMP-2 and MMP-9 expression was found in a number
of tumours in humans. It is most often associated with un-
favorable prognostic factors, such as the clinical advance-
ment of the disease, an infiltration to the surrounding
tissues, lymph node metastases and a shortened disease-
free survival [29–35]. However, not all studies associate
increased expressions of MMP-9 and MMP-2 in the
tumour tissue with a poor prognosis. For example, there
was a positive correlation between the presence of macro-
phages expressing high levels of MMP-9 in colorectal can-
cer and a decreased number of metastases [36]. Similarly,
Zhang et al. [37] analysed close to 100 cases of invasive
breast cancer in women and found no correlation between
high expression of MMP-9 and adverse prognostic factors.
Conclusion
We did not show significant differences in MMP-2, E-
cadherin and Ki-67 expression between metastatic and
non-metastatic tumours due to low number of cases
studied, however further experiments are necessary to
assess the role of these antigens in the process of canine
mammary tumours metastasis. Furthermore, the obtained
results may suggest that canine carcinomas may be used
as an experimental model for future studies on the
mechanism of carcinogenesis and metastasis in humans.
Nevertheless, the results of this study should be regarded
as preliminary, as the analysis was performed on a small
number of cases.
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